; (B) where the drug is originating; (C) whether any analogues to such drug present a substantial risk of abuse; (D) whether and to what extent the illicit supply of xylazine derives from the licit supply chain; and (E) recommendations for Congress with respect to whether xylazine should be transferred to another schedule under section 202 of the Controlled Substances Act ( 21 U.S.C. 812 ). (2) Additional report Not later than 3 years after the date of enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence of xylazine trafficking, misuse, and proliferation in the United States, including— (A) the status and results of research on the impact xylazine has on human health